C. Neuzillet

V. Bourgeois, J. Blanc, P. Michel, 2019, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

Immunotherapy in MSI/dMMR tumors in the perioperative setting: The IMHOTEP trial.

G. Piessen, F. Bibeau, F. Ghiringhelli, 2022, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

Translatome-based classification reveals a dual metabolic dependency of a new tumor subtype of pancreatic cancer

J. Iovanna, N. Dusetti, O. Larsson, 2020, bioRxiv.

Associations between the severity of medical and surgical complications and perception of surgeon empathy in esophageal and gastric cancer patients

S. Msika, A. Lièvre, J. Jougon, 2021, Supportive Care in Cancer.

Efficacy and safety of zenocutuzumab, a HER2 x HER3 bispecific antibody, across advanced NRG1 fusion (NRG1+) cancers.

A. Drilon, S. Ou, A. Joe, 2022, Journal of Clinical Oncology.

First-line chemotherapy plus immunotherapy in biliary tract cancer.

C. Neuzillet, 2022, The lancet. Gastroenterology & hepatology.

Infigratinib in pretreated cholangiocarcinoma with FGFR2 fusions or rearrangements.

C. Neuzillet, 2021, The lancet. Gastroenterology & hepatology.

Physical Activity as the Best Supportive Care in Cancer: The Clinician’s and the Researcher’s Perspectives

C. Neuzillet, F. Chorin, Victoire Cardot-Ruffino, 2022, Cancers.

FOLFIRI plus BEvacizumab or aFLIbercept after FOLFOX‐bevacizumab failure for COlorectal cancer (BEFLICO): An AGEO multicenter study

C. Tournigand, M. Perrier, D. Botsen, 2022, International journal of cancer.

Periostin‐ and podoplanin‐positive cancer‐associated fibroblast subtypes cooperate to shape the inflamed tumor microenvironment in aggressive pancreatic adenocarcinoma

S. Vacher, I. Bièche, C. Bousquet, 2022, The Journal of pathology.

Identification of two cancer-associated fibroblast markers revealing stromal heterogeneity in sustaining cancer progression and chemoresistance

C. Bousquet, C. Neuzillet, R. Samain, 2018, Translational Cancer Research.

Optimal oncologic management and mTOR inhibitor introduction are safe and improve survival in kidney and liver allograft recipients with de novo carcinoma

C. Tournigand, L. Salomon, A. De la taille, 2018, International journal of cancer.

Prognostic Value of Fusobacterium nucleatum after Abdominoperineal Resection for Anal Squamous Cell Carcinoma

N. Rioux-Leclercq, S. Vacher, A. Lièvre, 2022, Cancers.

Nutrition and physical activity professional education in gastrointestinal oncology: a national multidisciplinary survey

A. Foucaut, C. Neuzillet, A. Pellat, 2020, BMJ Supportive & Palliative Care.

Targeting the Ras–ERK pathway in pancreatic adenocarcinoma

E. Raymond, A. Couvelard, P. Hammel, 2013, Cancer and Metastasis Reviews.

Unraveling galectin-1 as a novel therapeutic target for cancer.

E. Raymond, S. Faivre, S. Albert, 2014, Cancer treatment reviews.

Everolimus affects vasculogenic mimicry in renal carcinoma resistant to sunitinib

I. Bièche, E. Raymond, S. Faivre, 2016, Oncotarget.

[De novo cancer after solid organ transplantation: Epidemiology, prognosis and management].

C. Tournigand, C. Duvoux, P. Grimbert, 2017, Bulletin du cancer.

Cancer-Associated Fibroblasts: Accomplices in the Tumor Immune Evasion

C. Bousquet, C. Neuzillet, R. Nicolle, 2020, Cancers.

Continuum of care for advanced biliary tract cancers.

C. Neuzillet, A. Vienot, 2020, Clinics and research in hepatology and gastroenterology.

Immune Therapy for Liver Cancers

C. Neuzillet, B. Rousseau, M. Hilmi, 2019, Cancers.

Digestive System Mixed Neuroendocrine-Non-Neuroendocrine Neoplasms

P. Ruszniewski, O. Bouché, A. Couvelard, 2017, Neuroendocrinology.

Angiogenesis and immune checkpoint inhibitors as therapies for hepatocellular carcinoma: current knowledge and future research directions

J. Pawlotsky, J. Calderaro, C. Neuzillet, 2019, Journal of Immunotherapy for Cancer.

Immune therapies in pancreatic ductal adenocarcinoma: Where are we now?

C. Neuzillet, L. Bartholin, M. Hilmi, 2018, World journal of gastroenterology.

Unravelling the pharmacologic opportunities and future directions for targeted therapies in gastro‐intestinal cancers Part 1: GI carcinomas

C. Tournigand, H. Kocher, C. Neuzillet, 2017, Pharmacology & therapeutics.

Combining immunotherapy with an epidrug in squamous cell carcinomas of different locations: rationale and design of the PEVO basket trial

N. Girard, I. Bièche, F. André, 2021, ESMO open.

Polymerase proofreading domain mutations: New opportunities for immunotherapy in hypermutated colorectal cancer beyond MMR deficiency.

C. Tournigand, C. Neuzillet, C. Joly, 2017, Critical reviews in oncology/hematology.

Maintenance therapies in metastatic pancreatic cancer: present and future with a focus on PARP inhibitors

C. Vitellius, P. Hammel, C. Neuzillet, 2020, Therapeutic advances in medical oncology.

Prognostic stratification of resected pancreatic ductal adenocarcinoma: Past, present, and future.

C. Neuzillet, J. Cros, L. Bartholin, 2018, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

High c‐Met expression in stage I–II pancreatic adenocarcinoma: proposal for an immunostaining scoring method and correlation with poor prognosis

V. Paradis, E. Raymond, P. Bedossa, 2015, Histopathology.

Unravelling the pharmacologic opportunities and future directions for targeted therapies in gastro-intestinal cancers part 2: Neuroendocrine tumours, hepatocellular carcinoma, and gastro-intestinal stromal tumours.

C. Tournigand, O. Mir, P. Ruszniewski, 2018, Pharmacology & therapeutics.

Optimizing Patient Pathways in Advanced Biliary Tract Cancers: Recent Advances and a French Perspective

E. Assenat, J. Sabourin, R. Coriat, 2023, Targeted Oncology.

Cholangiocarcinoma: what are the options in all comers and how has the advent of molecular profiling opened the way to personalised medicine ?

A. Lièvre, D. Malka, C. Neuzillet, 2022, European journal of cancer.

Inter‐ and intra‐tumoural heterogeneity in cancer‐associated fibroblasts of human pancreatic ductal adenocarcinoma

J. Kleeff, V. Paradis, A. Sadanandam, 2019, The Journal of pathology.

Perspectives of TGF-β inhibition in pancreatic and hepatocellular carcinomas

E. Raymond, S. Faivre, A. de Gramont, 2013, Oncotarget.

Predictive Biomarkers of Response to mTOR Inhibitors

E. Raymond, S. Faivre, C. Neuzillet, 2016 .

Stromal expression of SPARC in pancreatic adenocarcinoma

E. Raymond, S. Faivre, P. Hammel, 2013, Cancer and Metastasis Reviews.

The Immune Landscape of Human Pancreatic Ductal Carcinoma: Key Players, Clinical Implications, and Challenges

Marie Muller, L. Peyrin-Biroulet, C. Neuzillet, 2022, Cancers.

Intramural duodenal hematoma as a complication of paraduodenal pancreatitis.

S. Msika, J. Sabate, P. Jouët, 2011, Clinics and research in hepatology and gastroenterology.

Identification of a large intra-exonic deletion in BRCA2 exon 18 in a pancreatic ductal adenocarcinoma

S. Vacher, I. Bièche, E. Girard, 2023, Therapeutic advances in medical oncology.

Modified FOLFIRINOX Versus CISGEM Chemotherapy for Patients With Advanced Biliary Tract Cancer (PRODIGE 38 AMEBICA): A Randomized Phase II Study

V. Bourgeois, F. Ghiringhelli, R. Coriat, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Time from first seen in specialist care to surgery does not influence survival outcome in patients with upfront resected pancreatic adenocarcinoma

J. Regimbeau, R. Kianmanesh, C. Neuzillet, 2021, BMC Surgery.

Time intervals to diagnosis and chemotherapy do not influence survival outcome in patients with advanced pancreatic adenocarcinoma.

M. Brasseur, D. Botsen, O. Bouché, 2020, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

Validated Nomogram Predicting 6-Month Survival in Pancreatic Cancer Patients Receiving First-Line 5-Fluorouracil, Oxaliplatin, and Irinotecan.

E. Vasile, A. Lièvre, M. Aglietta, 2019, Clinical colorectal cancer.

Pancreatic cancer: Best supportive care.

C. Neuzillet, A. Védié, 2019, Presse medicale.

Pancreatic cancer: French clinical practice guidelines for diagnosis, treatment and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, ACHBT, AFC).

T. Conroy, O. Bouché, P. Hammel, 2018, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

Severe hyponatremia caused by nab-paclitaxel-induced syndrome of inappropriate antidiuretic hormone secretion

C. Neuzillet, S. Babai, Hervé Le-Louët, 2016, Medicine.

State of the art and future directions of pancreatic ductal adenocarcinoma therapy.

C. Tournigand, A. Sauvanet, A. Couvelard, 2015, Pharmacology & therapeutics.

Rationale and design of the Adapted Physical Activity in advanced Pancreatic Cancer patients (APACaP) GERCOR (Groupe Coopérateur Multidisciplinaire en Oncologie) trial: study protocol for a randomized controlled trial

F. Bonnetain, P. Hammel, C. Neuzillet, 2015, Trials.

Targeting cancer cell metabolism in pancreatic adenocarcinoma

E. Raymond, S. Faivre, A. de Gramont, 2015, Oncotarget.

FOLFIRI regimen in metastatic pancreatic adenocarcinoma resistant to gemcitabine and platinum-salts.

E. Raymond, P. Ruszniewski, F. Bonnetain, 2012, World journal of gastroenterology.

Prognostic factors for resectable pancreatic adenocarcinoma.

A. Sauvanet, P. Hammel, C. Neuzillet, 2011, Journal of visceral surgery.

Patient healthcare trajectories of intrahepatic cholangiocarcinoma in France: A nationwide retrospective analysis

A. Lièvre, C. Neuzillet, C. Emery, 2022, The Lancet regional health. Europe.

Contribution and limits of a non-intrusive Raman spectroscopic method compared with HPLC for routine application to pre-delivery analytical control of two major camptothecin analogs: irinotecan and topotecan

C. Neuzillet, F. Ader, A. Baillet-Guffroy, 2015 .

Professional and Psychological Impacts of the COVID-19 Pandemic on Oncology Residents: A National Survey

C. Neuzillet, A. Boilève, M. Hilmi, 2020, JCO global oncology.

Gastric Juvenile Polyposis with High-Grade Dysplasia in Pachydermoperiostosis

P. Ruszniewski, P. Hammel, Y. Panis, 2011, Case Reports in Gastroenterology.

Schwann cells support oncogenic potential of pancreatic cancer cells through TGFβ signaling

V. Hervieu, R. Tomasini, R. Pommier, 2019, Cell Death & Disease.

Best Supportive Care in Advanced Pancreatic Cancer

C. Neuzillet, A. Védié, 2021 .

Pancreatic ductal adenocarcinoma in BRCA2 mutation carriers.

V. Rebours, P. Hammel, N. Soufir, 2016, Endocrine-related cancer.

Overall Survival Prediction and Usefulness of Second-Line Chemotherapy in Advanced Pancreatic Adenocarcinoma

C. Tournigand, C. Borg, O. Bouché, 2017, Journal of the National Cancer Institute.

Cholangiocarcinoma: the quest for a second-line systemic treatment

C. Neuzillet, A. Vienot, 2019, Translational cancer research.

Prediction of survival with second-line therapy in biliary tract cancer: Actualisation of the AGEO CT2BIL cohort and European multicentre validations.

E. Vasile, A. Lièvre, W. Cacheux, 2019, European journal of cancer.

Pancreatic cancer and diabetes mellitus

C. Neuzillet, L. Mestier, 2013 .

Modulation of Collagen and MMP-1 Gene Expression in Fibroblasts by the Immunosuppressive Drug Rapamycin

L. Michel, D. Farge, F. Verrecchia, 2006, Journal of Biological Chemistry.

FAK activity in cancer‐associated fibroblasts is a prognostic marker and a druggable key metastatic player in pancreatic cancer

D. Schlaepfer, R. Tomasini, C. Jean, 2020, EMBO molecular medicine.

Pharmacologic Normalization of Pancreatic Cancer-Associated Fibroblast Secretome Impairs Prometastatic Cross-Talk With Macrophages

I. Bièche, R. Tomasini, C. Jean, 2021, Cellular and molecular gastroenterology and hepatology.

Biomarkers in Hepatobiliary Cancers: What Is Useful in Clinical Practice?

C. Neuzillet, A. Tijeras-Raballand, A. Boilève, 2021, Cancers.

Prognostic value of intratumoral Fusobacterium nucleatum and association with immune-related gene expression in oral squamous cell carcinoma patients

O. Mariani, J. Klijanienko, S. Vacher, 2021, Scientific Reports.

Risk factors for Coronavirus Disease 2019 (COVID-19) severity and mortality among solid cancer patients and impact of the disease on anticancer treatment: A French nationwide cohort study (GCO-002 CACOVID-19)

N. Magné, B. Chauffert, F. Ducray, 2020, European Journal of Cancer.

Contemporary Outcomes for the Curative Treatment of Colorectal Cancer Pulmonary Metastases

C. Neuzillet, J. Assouad, R. Lupinacci, 2023, Journal of gastrointestinal cancer.

Stromal expression of SPARC in pancreatic adenocarcinoma

E. Raymond, S. Faivre, P. Hammel, 2013, Cancer and Metastasis Reviews.

Intratumoral microbiome is driven by metastatic site and associated with immune histopathological parameters: An ancillary study of the SHIVA clinical trial.

S. Vacher, I. Bièche, N. Servant, 2023, European journal of cancer.

First-line antiangiogenics for metastatic renal cell carcinoma: A systematic review and network meta-analysis.

C. Tournigand, L. Salomon, A. De la taille, 2016, Critical reviews in oncology/hematology.

Autoimmune pancreatitis with atypical imaging findings that mimicked an endocrine tumor.

P. Rougier, P. Hammel, L. Palazzo, 2010, World journal of gastroenterology.

Obesity, cancer, and response to immune checkpoint inhibitors: Could the gut microbiota be the mechanistic link?

C. Neuzillet, S. Assoun, Adrien Rousseau, 2023, Pharmacology & therapeutics.

Microbiome and pancreatic ductal adenocarcinoma.

I. Bièche, C. Neuzillet, A. Tijeras-Raballand, 2021, Clinics and research in hepatology and gastroenterology.

Management of pancreatic ductal adenocarcinoma (PDAC): Progress in the past decade and challenges for the future

C. Neuzillet, M. Leo, Granier Sandra, 2019, Cancer Reports and Reviews.

Primary tumor resection in colorectal cancer with unresectable synchronous metastases: A review.

J. Vaillant, O. Bouché, J. Spano, 2014, World journal of gastrointestinal oncology.

Tepotinib plus cetuximab in patients (pts) with RAS/BRAF wild-type left-sided metastatic colorectal cancer (mCRC) and acquired resistance to anti-EGFR antibody therapy due to MET amplification (METamp).

J. Tabernero, T. Bekaii-Saab, Z. Wainberg, 2021 .

Mechanistic Signatures of Human Papillomavirus Insertions in Anal Squamous Cell Carcinomas

A. Nicolas, O. Mariani, R. Rouzier, 2019, Cancers.

Efficacy and safety of zenocutuzumab in advanced pancreas cancer and other solid tumors harboring NRG1 fusions.

S. Ou, A. Joe, A. Schram, 2021, Journal of Clinical Oncology.

[Physical activity after breast cancer diagnosis and survival: A systematic review].

R. Rouzier, C. Bonneau, C. Neuzillet, 2020, Bulletin du cancer.

Is primary tumor resection associated with a longer survival in colon cancer and unresectable synchronous metastases? A 4-year multicentre experience.

O. Bouché, R. Kianmanesh, C. Neuzillet, 2014, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

Pancreatic cancer orthotopic graft in a murine model

C. Jean, C. Bousquet, C. Neuzillet, 2023, Acta cirurgica brasileira.

Nutrition Support in Pancreatic Cancer: An Expert Statement on Practical Implementation of French Guidelines.

J. Taieb, C. Neuzillet, P. Pessaux, 2023, Clinics and research in hepatology and gastroenterology.

[Biliary tract cancers: new medical therapeutic approaches guided by molecular data].

C. Neuzillet, M. Delaye, 2022, Annales de pathologie.

Translatome-based classification reveals a dual metabolic dependency of a new tumor subtype of pancreatic cancer

J. Iovanna, N. Dusetti, O. Larsson, 2020, bioRxiv.

Schwann cells support oncogenic potential of pancreatic cancer cells through TGFβ signaling

V. Hervieu, R. Tomasini, Laura Broutier, 2019, Cell Death & Disease.

High c‐Met expression in stage I–II pancreatic adenocarcinoma: proposal for an immunostaining scoring method and correlation with poor prognosis

V. Paradis, E. Raymond, P. Bedossa, 2015, Histopathology.

[Medical management of cholangiocarcinomas in 2015].

C. Tournigand, B. Rousseau, C. Neuzillet, 2016, Bulletin du cancer.

Targeting the Ras–ERK pathway in pancreatic adenocarcinoma

E. Raymond, A. Couvelard, P. Hammel, 2012, Cancer and Metastasis Reviews.

Effect of Adapted Physical Activity in Patients With Advanced Pancreatic Cancer: The APACaP GERCOR Randomized Trial.

C. Neuzillet, F. Desseigne, B. Chibaudel, 2023, Journal of the National Comprehensive Cancer Network : JNCCN.

Chemotherapy with or without selective internal radiation therapy for intrahepatic cholangiocarcinoma: Data from clinical trials

K. Boudjema, J. Bridgewater, Y. Rolland, 2023, Hepatology.

Ampullary tumors: French Intergroup Clinical Practice Guidelines for diagnosis, treatments and follow-up (TNCD, SNFGE, FFCD, UNICANCER, GERCOR, SFCD, SFED, ACHBT, AFC, SFRO, RENAPE, SNFCP, AFEF, SFP, SFR).

C. Vitellius, M. Vullierme, C. Neuzillet, 2024, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.